CLINICAL LAB MEDICARE COMPETITIVE BIDDING OPPOSED IN OCT. 31 LETTER FROM INDUSTRY/MEDICAL GROUPS; PROJECT TARGETS CHEMISTRY, HEMATOLOGY, SEROLOGY TESTS
This article was originally published in The Gray Sheet
Executive Summary
Medicare competitive bidding for clinical laboratory services should be delayed for at least two years, a group of laboratory and medical associations say in an Oct. 31 letter to Nancy-Ann Minn DeParle, acting administrator of the Health Care Financing Administration.
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.